Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.
EJHaem
December 2024
Johnson & Johnson Innovative Medicine Lisbon Portugal.
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period.
Methods: A retrospective cohort multicenter study using secondary data of national hospital drug consumption database from 11 Portuguese public hospitals between 2017 and 2022.
Results: Number of MM-treated patients increased 53% over 5 years (from 825 to 1266 patients).
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Blood Cancer J
November 2024
Hematology Department, CHU Nantes, Nantes, France.
The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab-pomalidomide-dexamethasone vs. pomalidomide-dexamethasone) and IKEMA (isatuximab-carfilzomib-dexamethasone vs.
View Article and Find Full Text PDFIndirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.
J Dermatol
December 2024
Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Expanding the systemic treatment options for patients with psoriasis, deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor is approved in the United States, European Union, China, Japan, Taiwan, Korea, and other countries for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients. This systematic review and network meta-analysis (NMA) evaluated the clinical efficacy associated with deucravacitinib and other biologic or non-biologic systemic treatments for moderate to severe plaque psoriasis in Asian populations.
View Article and Find Full Text PDFBelantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.
Blood Cancer J
September 2024
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this group of triple class exposed/refractory (TCE/R) patients is crucial. Here we present a post-hoc subgroup analysis of TCE/R patients treated on the ALGONQUIN study of belantamab mafodotin plus pomalidomide-dexamethasone (belamaf-Pd) for relapsed MM.
View Article and Find Full Text PDFIxazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
November 2024
Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Article Synopsis
- The study evaluates the effectiveness of a treatment regimen (ixazomib, thalidomide, and dexamethasone) followed by maintenance with ixazomib after salvage autologous hematopoietic stem-cell transplantation (HSCT) for patients with relapsed multiple myeloma, compared to observation.
- Conducted as part of a larger trial (Myeloma XII) across 79 UK hospitals, it involved patients aged 18+ with measurable disease and certain health criteria, randomized into two treatment groups.
- The primary measurement for effectiveness was progression-free survival, with safety assessments also being conducted, and a total of 206 patients participated in this phase of the trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!